While these results are promising, more dedicated preclinical and clinical studies are needed to evaluate the therapeutic potential of CCR2 inhibitors specifically in tumor patients, particularly those with F. nucleatum-associated or adipocyte-rich tumors. Here, CCR2 is linked to neoplasm.